Literature DB >> 764929

Renin concentrations and effects of propranolol and spironolactone in patients with hypertension.

B E Karlberg, B Kågedal, L Tegler, K Tolagen.   

Abstract

In a crossover study 32 patients with hypertension were randomly allocated to treatment with spironolactone 200 mg/day for two months, propranolol 320 mg/day for two months, and a combination of both drugs at half the dose. Between the treatments placebo was given for two months. Both spironolactone and propranolol lowered the blood pressure significantly in both positions. The initial plasma renin activity (PRA) levels ranged from 0-4 to 5-0 mug angiotensin I l-1 h-1, and there was a close correlation between these levels and the effects of the drugs: with increasing PRA the response to propranolol was better while the opposite was true for spironolactone. Spironolactone reduced the blood pressure more at eight than at four weeks, while no such difference could be shown for propranolol. Spironolactone and propranolol together decreased the blood pressure still further irrespective of the initial PRA. All patients achieved a normal supine blood pressure.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 764929      PMCID: PMC1638563          DOI: 10.1136/bmj.1.6004.251

Source DB:  PubMed          Journal:  Br Med J        ISSN: 0007-1447


  22 in total

1.  Low-renin hypertension. Restoration of normotension and renin responsiveness.

Authors:  R F Spark; C M O'Hare; R M Regan
Journal:  Arch Intern Med       Date:  1974-02

2.  The effct of propranolol on plasma renin activity and blood pressure in mild essential hypertension.

Authors:  L Hansson; A J Zweifler
Journal:  Acta Med Scand       Date:  1974-05

3.  Relation of age, diastolic pressure and known duration of hypertension to presence of low renin essential hypertension.

Authors:  M L Tuck; G H Williams; J P Cain; J M Sullivan; R G Dluhy
Journal:  Am J Cardiol       Date:  1973-10       Impact factor: 2.778

4.  Application of a radioimmunoassay for angiotensin I to the physiologic measurements of plasma renin activity in normal human subjects.

Authors:  E Haber; T Koerner; L B Page; B Kliman; A Purnode
Journal:  J Clin Endocrinol Metab       Date:  1969-10       Impact factor: 5.958

5.  Volume factor in low and normal renin essential hypertension. Treatment with either spironolactone or chlorthalidone.

Authors:  E D Vaughan; J H Laragh; I Gavras; F R Bühler; H Gavras; H R Brunner; L Baer
Journal:  Am J Cardiol       Date:  1973-09-20       Impact factor: 2.778

6.  Simplified radioimmunoassay for serum aldosterone utilizing increased antibody specificity.

Authors:  J K McKenzie; J A Clements
Journal:  J Clin Endocrinol Metab       Date:  1974-04       Impact factor: 5.958

7.  Spironolactone and hydrochlorothiazide in essential hypertension. Blood pressure response and plasma renin activity.

Authors:  E V Adlin; A D Marks; B J Channick
Journal:  Arch Intern Med       Date:  1972-12

8.  Propranolol inhibition of renin secretion. A specific approach to diagnosis and treatment of renin-dependent hypertensive diseases.

Authors:  F R Bühler; J H Laragh; L Baer; E D Vaughan; H R Brunner
Journal:  N Engl J Med       Date:  1972-12-14       Impact factor: 91.245

9.  The syndrome of essential hypertension and suppressed plasma renin activity. Normalization of blood pressure with spironolactone.

Authors:  R M Carey; J G Douglas; J R Schweikert; G W Liddle
Journal:  Arch Intern Med       Date:  1972-12

10.  Low-renin hypertension: nephrosclerosis?

Authors:  J D Swales
Journal:  Lancet       Date:  1975-01-11       Impact factor: 79.321

View more
  4 in total

Review 1.  Renin and beta-adenoceptor blockade-the mechanism of the hypotensive effect?

Authors:  J Hamer
Journal:  Br J Clin Pharmacol       Date:  1976-06       Impact factor: 4.335

2.  Adding low-dose spironolactone to multidrug regimens for resistant hypertension.

Authors:  Kathleen H Berecek; Amal Farag; Gul Bahtiyar; Jeffery Rothman; Sammy I McFarlane
Journal:  Curr Hypertens Rep       Date:  2004-06       Impact factor: 5.369

3.  Raised aldosterone to renin ratio predicts antihypertensive efficacy of spironolactone: a prospective cohort follow-up study.

Authors:  P O Lim; R T Jung; T M MacDonald
Journal:  Br J Clin Pharmacol       Date:  1999-11       Impact factor: 4.335

4.  A standard approach to compiling clinical pharmacokinetic data.

Authors:  L B Sheiner; L Z Benet; L A Pagliaro
Journal:  J Pharmacokinet Biopharm       Date:  1981-02
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.